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Abstract
Background: The cellular and molecular mechanisms of tumour response following chemotherapy are largely unknown. We
found that low dose anti-tumour agents up-regulate early growth response 1 (EGR1) expression. EGR1 is a member of the
immediate-early gene group of transcription factors which modulate transcription of multiple genes involved in cell
proliferation, differentiation, and development. It has been reported that EGR1 act as either tumour promoting factor or
suppressor. We therefore examined the expression and function of EGR1 in osteosarcoma.
Methods: We investigated the expression of EGR1 in human osteosarcoma cell lines and biopsy specimens. We next
examined the expression of EGR1 following anti-tumour agents treatment. To examine the function of EGR1 in
osteosarcoma, we assessed the tumour growth and invasion in vitro and in vivo.
Results: Real-time PCR revealed that EGR1 was down-regulated both in osteosarcoma cell lines and osteosarcoma patients’
biopsy specimens. In addition, EGR1 was up-regulated both in osteosarcoma patient’ specimens and osteosarcoma cell lines
following anti-tumour agent treatment. Although forced expression of EGR1 did not prevent osteosarcoma growth, forced
expression of EGR1 prevented osteosarcoma cell invasion in vitro. In addition, forced expression of EGR1 promoted down-
regulation of urokinase plasminogen activator, urokinase receptor, and urokinase plasminogen activity. Xenograft mice
models showed that forced expression of EGR1 prevents osteosarcoma cell migration into blood vessels.
Conclusions: These findings suggest that although chemotherapy could not prevent osteosarcoma growth in
chemotherapy-resistant patients, it did prevent osteosarcoma cell invasion by down-regulation of urokinase plasminogen
activity via up-regulation of EGR1 during chemotherapy periods.
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Introduction
Osteosarcoma is the most frequent primary malignant bone
tumor. After initial diagnosis is made by biopsy, treatment consists
of preoperative chemotherapy, followed by definitive surgery and
postoperative chemotherapy. The Survival rates for patients
treated with intensive multidrug chemotherapy and aggressive
local control have been reported at 60–80% [1–5]. Indeed,
patients with non-metastatic disease have a 70% chance of long-
term survival. Eighty percent of patients die of metastatic disease,
most commonly in the lungs [3]. Unfortunately, patients with
metastatic disease at diagnosis or those who have recurrent disease
have a poor prognosis, with only 20% surviving at 5 years,
indicating that new therapeutic options for them need to be
actively explored [6,7].
The early growth response gene 1 (EGR1) is a member of the
immediate-earlygenegroup oftranscriptionfactorswhichmodulate
transcription of multiple genes involved in cell proliferation,
differentiation, and development [8]. Expression of EGR1 is
significantly reduced in a number of tumor cells [9,10], and loss
of expression of it is closely associated with tumor formation in
mammalian cells and tissues [10]. On the other hand, stable
expression of EGR1 inhibited cell proliferation and soft agar growth
in NIH3T3 cells transformed with v-sis, indicating that EGR1
functions as a tumor suppressor [11]. We therefore examined the
expression and function of EGR1 in osteosarcoma. Here, we report
that expression of EGR1 is down-regulated in human osteosarcoma
cell lines and patient’ biopsy specimens. In addition, treatment with
anti-tumour agents promoted up-regulation of EGR1. Although
forced expression of EGR1 did not affect osteosarcoma growth,
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16234forced expression of EGR1 inhibited osteosarcoma cell invasion by
down-regulation of urokinase plasminogen activator (uPA) and
urokinase receptor (uPAR).
Materials and Methods
Cell culture
143B, Saos-2, HOS, and MG63 cells were purchased from the
American Type Culture Collection (ATCC, USA). NOS-1 was
provided by the RIKEN BRC through the National Bio-Resource
Project of The MEXT, Japan (Tsukuba, Japan) [12]. Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FBS, penicillin (100 U/ml), and streptomycin
(100 mg/ml). Human osteoblast cells (NHOst) were purchased
from Sanko Junyaku (Tokyo, Japan). NHOst was cultured with
OBM
TM (Cambrex, East Rutherford, NJ, USA) or DMEM
supplemented with 10% FBS. All cells were grown in a humidified
atmosphere containing 5% CO2 at 37uC.
Anti-tumor agents
Doxorubicin, methotrexate, and etoposide were purchased from
Sigma-Aldrich (MO, USA). Cisplatin was purchased from LKT
laboratories (MN, USA).
Patient’ specimens
All human osteosarcoma biopsy specimens were obtained from
primary lesions. Biopsy was performed before chemotherapy or
radio therapy to make the diagnosis. Normal bone tissue was
obtained from femur during total hip arthroplasty. Specimens of
OS6, OS8, and OS9 tumors were obtained during tumor
resection in osteosarcoma patients who received chemotherapy.
Doxrubicin, methotrexate, and cisplatin were given to these three
patients according to COSS-86 protocol. We compared the EGR1
expressions in the biopsy specimens and the resected tumor
specimens obtained from these patients. The study protocol was
approved by the institutional review board of the Kagoshima
University. All patients and controls gave written informed
consent.
Real-time PCR
For real-time PCR, total RNA was obtained 24 h, 48 h, and 5
days following drug treatment. DNase-treated and reverse-
transcribed using oligo(dT) primers as described by the manufac-
turer (Invitrogen, Carlsbad, CA, USA). Reactions were run using
SYBR Green (BIO-RAD, Hercules, CA, USA) on a MiniOpti-
con
TM machine (BIO-RAD). The comparative Ct (DDCt) method
was used to determine fold change in expression using GAPDH or
ACTB. Each sample was run minimally at three concentrations in
triplicate. All primer sets amplified 150- to 200-bp fragments. The
primers sequences used were follows: for EGR1: 5-CAG-
CACCTTCAACCCTCAG-3, 5- CACAAGGTGTTGCCACT-
GTT-3; uPA: 5- TGTGAGATCACTGGCTTTGG-3, 5- GTCA-
GCAGCACACAGCATTT-3; uPAR: 5- TGAAGAACAGTGC-
CTGGATG-3, 5- TGTTGCAGCATTTCAGGAAG-3; GAPDH:
5- GAAGGTGAAGGTCGGAGTC-3, 5- GAAGATGGTGAT-
GGGATTTC-3; ACTB: 5-AGAAAATCTGGCACCACACC-3,
5-AGAGGCGTACAGGGATAGCA-3.
MTT assay
Following 100 ng–1 mg cisplatin, 1 ng–10 ng methotrexate,
50 ng–1000 ng etoposide, or 10 ng–100 ng doxorubicin treat-
ment, we performed MTT assay to evaluate the osteosarcoma
growth as previously reported [13]. In addition, we transfected
control vector or EGR1 expression vector, and examined
osteosarcoma cell growth by MTT assay. Cells were incubated
with substrate for MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) for 4 hours, and washed with PBS and lysed
to release formazan from cells. Then cells were analyzed in a
Safire microplate reader (BIO-RAD) at 562 nm.
Vector transfection
EGR1 expression vector was purchased from Origene (Mary-
land, USA). EGR1 was cloned into pCMV6-Entry Neomycin
Vector. Lipofection of expression vector was performed as
recommended in the supplier’s protocol using FuGENE 6 (Roche,
Basel, Switzerland). All transfected cells were treated with
neomycin constitutively to obtain stable transfectants. EGR stable
transfectants were used for invasion assay, examinations of uPA
and uPAR expressions, and in vivo experiments.
Colony formation assay
Colony formation assay was performed as previously described
[14]. Briefly, cells were suspended in DMEM containing 0.33%
agar and 10% fetal bovine serum and plated onto the bottom layer
containing 0.5% agar. The cells were plated at a density of 5610
3
per well in a 24-well plate, and colonies were counted 14 days later.
Each condition was analyzed in triplicate, and all experiments were
repeated three times.
Invasion assay
Invasion of osteosarcoma cells was measured using the BD
BioCoat
TM BD Matrigel
TM Invasion Chamber (BD Bioscience,
NJ, U.S.A.) according to the manufacturer’s protocol. Briefly, the
cells were transfected with plasmids and selected by neomycin.
Osteosarcoma cells were seeded onto the membrane of the upper
chamber of the transwell at a concentration of 3–5610
5/ml in
2 ml of DMEM medium. The medium in the upper chamber was
serum-free. The medium in the lower chamber contained 5% fetal
calf serum as a source of chemoattractants. Cells that passed
through the Matrigel-coated membrane were stained with Diff-
Quik (Sysmex, Kobe, Japan) and photographed.
Western blot
Western blot analysis was performed as previously reported
[15]. Briefly, cells were lysed using NP40 lysis buffer (0.5% NP40,
10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 3 mM pAPMSF
(Wako Chemicals, Kanagawa, Japan), 5 mg/ml aprotinin (Sigma,
StLouis, USA), 2 mM sodium orthovanadate (Wako Chemicals,
Kanagawa, Japan), and 5 mM EDTA). Lysates were subjected to
SDS-PAGE and subsequent immunoblotting was performed.
Following antibodies were used: ant- EGR1 and anti-beta actin
(Santa Cruz, CA. U.S.A). Detection was performed using the ECL
detection system (Amersham, Giles, UK).
uPA activity assay
uPA activity assay was performed with cell extracts according to the
manufacturer’s instructions, with absorption measured at 340 nm
(InnovativeResearch,MI,U.S.A.).Theassaymeasuresonlytheactive
speciesofuPA,andastandardcurvewasgeneratedusingrecombinant
activeuPA.Theassayconditionswereoptimizedsothattheamountof
tissue extract or cell extract added gave rise to uPA activity within the
l i n e a rr a n g eo fd e t e c t i o n .E a c hr e a c t i o nw a sp e r f o r m e di nt r i p l i c a t e ,
and all experiments were repeated for three times.
Xenograft model of osteosarcoma
For subcutaneous xenograft models, 143B cells were suspended
in 100 mL Matrigel (BD, NJ USA.). Cell suspensions were
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inoculation, 4 mg/kg doxorubicin was administered by intraper-
itoneal injection. One day after treatment, mice were scarified and
tumors were examined. For metastasis experiments, 143B cells
(5610
5) were transfected with GFP lentiviral particles (Santa Cruz,
CA. U.S.A). Stably-GFP-expressing 143B cells (1610
6) were
mixed with a collagen gel in a 1:1 volume, and inoculated into
the left knee joint of 6-weeks-old nude mice. Five weeks after
inoculation, the mice were sacrificed. GFP-positive-143B cells
were counted in 50 ml blood aspirates from hearts using the M165
FC microscope (Leica Microsystems, Wild Heerbrugg, Switzer-
land). Metastatic nodules in the lungs were evaluated by direct
microscopic visualization using an M165 FC microscope. Lung
metastasis area was calculated by Lumina Vision (Mitani
Corporation, Tokyo, Japan). All experimental procedures were
performed in compliance with the guiding principles for the Care
and Use of Animals described in the American Journal of
Physiology and with the Guidelines established by the Institute of
Laboratory Animal Sciences, Faculty of Medicine, Kagoshima
University (approval number: 20064). All efforts were made to
minimize animal suffering, to reduce the number of animals used,
and to utilize possible alternatives to in vivo techniques.
ELISA
Expression levels of uPA and uPAR proteins were assayed using
specific enzyme-linked immunosorbent assay kits according to the
manufacturer’s instructions (Abnova, Taipei, Taiwan). Cell lysates
were collected by EGR1 stable transfected osteosarcoma cells.
Statistics
Each sample was analyzed in triplicate, and experiments were
repeated three times. In all figures, error bars are standard
deviations. All statistical analyses were performed using Microsoft
Office Excel (Microsoft, Albuquerque, New Mexico, USA) and
STASTISCA (StatSoft, Tulsa, OK, USA). Differences between
mean values were evaluated by the unpaired t-test, and differences
in frequencies by Fisher’s exact test. Differences were considered
significant at P,0.05.
Results
EGR1 is down-regulated in osteosarcoma cell lines and
patient’ specimens
Real-time PCR was performed to examine the gene expression
of EGR1 in osteoblast and osteosarcoma cell lines including
NHOst, 143B, Saos-2, HOS, MG63, and NOS-1. Real-time PCR
revealed that the 5 of 5 osteosarcoma cell lines exhibited 0.002- to
0.369-fold decreased in expression of EGR1 (Figure 1A). In
addition, we performed real-time PCR using patient’ biopsy
specimens. Real-time PCR revealed that EGR1 was decreased
0.01-to 0.2-fold in 8 of 10 human biopsy specimens (Figure 1B).
These findings suggest that the EGR1 is down-regulated in human
osteosarcomas.
Anti-tumour agent treatment promoted up-regulation of
EGR1
To examine the effects of anti-tumour agents on EGR1
expression, we performed real-time PCR after anti-tumour agent
treatment. We attempt to clarify the changes in EGR1 expression
following low-dose anti-tumor agent treatment, and determined
anti-tumor drug concentrations required to prevent osteosarcoma
cell proliferation. MTT assay revealed that 250 ng/ml cisplatin,
1 ng/ml methotrexate, 50 ng/ml etoposide, or 10 ng/ml doxo-
rubicin treatment did not prevent 143B cell growth. Growth of
Saos-2 cells was not inhibited by 1 ng/ml methotrexate, 5 ng/ml
methotrexate, 10 ng/ml methotrexate, 50 ng/ml etoposide, or
10 ng/ml doxorubicin. On the other hand, Growth of 143B cell
and Saos-2 cell was inhibited by higher dose of each drug
(Figure 2 A, B). Following 24 h treatment with these
concentrations of anti-tumor drugs, EGR1 was up-regulated
(Figure 3 A–D). Following 48 h or 5 days treatment, cisplatin,
methotrexate, etoposide or doxorubicin increased EGR1 expres-
sion in 143B cell and Saos-2 cells (Figure S1). We next examined
the expression of EGR1 following chemotherapy in biopsy
specimens. Specimens of OS6, OS8, and OS9 tumors were
obtained during tumor resection in osteosarcoma patients who
received chemotherapy. We compared the EGR1 expressions in
the biopsy specimens and the resected tumor specimens obtained
from these patients. In 3 of 3 patient’ specimens examined, EGR1
expression was increased 7.87- to 1.71 following chemotherapy
(Figure S2A). To examine the expression of EGR1 following low-
dose chemotherapy in vivo, we used a novel osteosarcoma murine
xenograft model with 143B cells. We injected 4 mg/kg doxoru-
bicin which is less than one-hundred dose of COSS-86 protocol
for osteosarcoma patients. Real-time PCR showed that low dose
doxorubicin treatment promoted up-regulation of EGR1 in vivo
(Figure S2B).
Figure 1. Down-regulation of EGR1 in human osteosarcoma.
Total RNA extracted from osteosarcoma cell lines (A) and osteosarcoma
patients’ biopsy specimens (B) were analyzed by real-time PCR. Results
revealed that 5 of 5 human osteosarcoma cell lines and 8 of 10 human
biopsy specimens of osteosarcoma had decreased EGR1 expression. The
comparative Ct (DDCt) method was used to determine fold change in
expression using GAPDH. These experiments were performed in
triplicate with similar results.
doi:10.1371/journal.pone.0016234.g001
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growth
It has been reported that EGR1 over-expression suppresses the
growth of cell in soft agar and tumor growth in nude mice [10,16].
We therefore, transfected the EGR1 expression vector and
examined osteosarcoma cell growth. Western blot analysis showed
up-regulation of EGR1 in 143B, Saos-2, and HOS cells
(Figure 4A). MTT assay revealed that forced expression of
EGR1 did not prevent osteosarcoma growth in vitro (Figure
S3A). We next examined the effects of EGR1 on anchorage-
independent osteosarcoma growth. Colony formation assay
revealed that forced expression of EGR1 did not affect the
Figure 2. Osteosarcoma cell growth following anti-tumor drug treatment. MTT assay showed that growth at 48 h of 143B cells was not
inhibited by 250 ng cisplatin, 1 ng/ml methotrexate, 50 ng/ml etoposide, or 10 ng/ml doxorubicin. Growth of 143B cell was inhibited by higher dose
of each drug (A)( P ,0.05). Growth at 48 h of Saos-2 cells was not inhibited by 1 ng/ml methotrexate, 5 ng/ml methotrexate, 10 ng/ml methotrexate,
50 ng/ml etoposide, or 10 ng/ml doxorubicin. Growth of Saos-2 cell was inhibited by higher dose of each drug (B)( P ,0.05). The experiment was
performed in triplicate with similar results [error bars represent mean (SD)].
doi:10.1371/journal.pone.0016234.g002
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osteosarcoma cell lines were analyzed by real-time PCR. Treatment with cisplatin, methotrexate, etoposide or doxorubicin increased EGR1 expression
in 143B and Saos-2 cells. The comparative Ct (DDCt) method was used to determine fold change in expression using GAPDH or ACTB. Experiments
were performed in triplicate with similar results [error bars represent mean (SD)].
doi:10.1371/journal.pone.0016234.g003
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that up-regulation of EGR1 following anti-tumor agent treatment
had no effect on osteosarcoma cell growth.
Over-expression of EGR1 prevents osteosarcoma cell
invasion in vitro
To examine the effects of EGR1 up-regulation after anti-
tumour agent treatment in modulating the invasive activity of
osteosarcoma cells, in vitro invasive activity assays were
performed to assess the proportion of osteosarcoma cells
transfected with EGR1 expression vector or control vector that
invaded through matrigel-coated membranes. Significantly lower
proportions of 143B, Saos-2, and HOS cells transiently
transfected with EGR1 expression vector migrated through
matrigel-coated chambers than osteosarcoma cells transfected
with control vector (Figure 4B, C).
Figure 4. EGR1 prevents osteosarcoma cell invasion in vitro. Western blot analysis revealed that lysates of EGR1 expression vector-transfected
cells were positive for anti-EGR1 antibody (A). Cell invasion assay showed that forced expression of EGR1 decreased 143B, Saos-2, and HOS cell
invasion (B)( P ,0.05). These experiments were performed in triplicate with similar results [error bars represent mean (SD)].
doi:10.1371/journal.pone.0016234.g004
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We then examined the cellular mechanisms by which EGR1
exerts its effects on osteosarcoma cell invasion. Several investiga-
tions have shown that EGR1 plays an important role in the control
of tumor metastasis through regulation of cancer invasion-related
genes, including TGF-b1, thrombospondin-1, and plasminogen
activator inhibitor-1 [17,18]. We examined whether EGR1 affects
the expression of cancer invasion-related genes. Real-time PCR
revealed that forced expression of EGR1 in 143B, Saos-2, and
HOS osteosarcoma cell lines decreased the expression of uPA and
uPAR (Figure 5). ELISA revealed that forced expression of EGR1
decreased the expression of uPA and uPAR proteins (Figure S4).
Further, we examine the effects of anti-tumour agents on uPA and
uPAR expression in vitro, we performed real-time PCR after anti-
tumor agent treatment. Treatment of low dose anti-tumor drugs
decreased the expression of uPA and uPAR (Figure S5). To
examine the effects of low dose chemotherapy on uPA and uPAR
expression in vivo, we used osteosarcoma murine xenograft model
with 143B cells. Nude mice were treated with 4 mg/kg
doxorubicin. Real-time PCR showed that low dose doxrubicin
Figure 5. EGR1 decreased expression of uPA and uPAR. We examined whether EGR1 affects the expression of uPA and uPAR. RNA was
prepared from control vector or EGR1 expression vector stably transfected cells. Real-time PCR revealed that forced expression of EGR1 decreased
uPA and uPAR expression in 143B, Saos-2, and HOS cells (P,0.05). The comparative Ct (DDCt) method was used to determine fold change in
expression using GAPDH. These experiments were performed in triplicate with similar results [error bars represent mean (SD)].
doi:10.1371/journal.pone.0016234.g005
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S6A).
EGR1 down-regulates uPA activity
uPA is produced and secreted as an inactive single-chain
polypeptide, termed pro-uPA, which lacks plasminogen-activating
activity. The binding of pro-uPA to uPAR induces its activation
which in turn converts plasminogen to the active serine protease
plasmin [19]. In this regard, we examined whether EGR1 exerts
effects on uPA activity by performing uPA activity ELISA. ELISA
showed that forced expression of EGR1 in osteosarcoma cell lines
down-regulated the activity of uPA (Figure 6).
EGR1 suppresses osteosarcoma migration into blood
vessels in vivo
To investigate the effects of EGR1 on osteosarcoma tumor
migration and invasion in vivo, we used a novel osteosarcoma
murine xenograft model with 143B cells. Intrajoint inoculation of
GFP-positive 143B cells in nude mice induced primary osteosar-
coma tumor formation by 2 weeks after inoculation. These
primary tumors gave rise to microscopically detectible micro
metastases in the lungs within 5 weeks after inoculation. Although
we attempted to determine the volume of the primary tumors, we
were unable to do so because tumor had extended into muscle and
bone. RNA was prepared from tumor formed by control vector or
EGR1 expression vector transfected cells. Real-time PCR revealed
that forced expression of EGR1 decreased uPA and uPAR
expression in vivo (Figure S6B). After 5 weeks, we counted
GFP-positive- 143B cells within 50 ml blood aspirates from hearts.
The vector control group had an average of 51.2 cells, whereas the
EGR1 group averaged only 18.7 cells (Figure 7A, B). Lung
metastases were found in 6 of 6 control cell-inoculated mice. In
contrast, there were lung metastases in 4 of 6 EGR1-expressing
143B-inoculated mice. The percent of lung metastasis area was
calculated. The vector control group had an average of 0.6%
metastasis area, whereas the EGR1 group averaged 0.31%
metastasis area (Figure 7C). These findings show that EGR1
prevented osteosarcoma migration into blood vessel in vivo.
Discussion
Current standard regimens for osteosarcoma treatment include
preoperative and postoperative chemotherapy. The benefits of
chemotherapy have been demonstrated in many studies. Preop-
erative chemotherapy induces tumor necrosis in the primary
tumor facilitating surgical resection and enabling early treatment
of micrometastatic disease [20,21]. Among those patients who
received neoadjuvant treatment, chemotherapy-related tumor
necrosis was good in 62% and poor in 38% of patients [22].
Figure 6. EGR1 decreased uPA activity. uPA activity was examined using cell lysates. Cell lysate were prepared from control vector or EGR1
expression vector transfected cells. ELISA assay showed that EGR1 decreased uPA activity 0.40-fold in 143B (A). uPA activity was decreased 0.49-fold
by EGR1 in Saos-2 (B). Luciferase assay showed that EGR1 decreased uPA activity 0.57-fold in HOS (C). These experiments were in triplicate with similar
results [error bars represent mean (SD)] (P,0.05).
doi:10.1371/journal.pone.0016234.g006
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even poor responders to chemotherapy. Even though chemother-
apy is quite benefit for osteosarcoma patients, administration of
preoperative chemotherapy results in delay of surgical resection of
primary tumor. It is possible that new lung metastases will develop
during preoperative chemotherapy in poor or non-responders. We
showed that low-dose anti-tumor agent treatment up-regulated
EGR1 expression and that EGR1 prevented osteosarcoma
invasion via uPA/uPAR down-regulation. These findings suggest
that preoperative chemotherapy prevents the development of new
lung metastases in poor or non-responders. In addition, osteosar-
coma incidence rates in the United States peak in adolescence and
in the elderly [23]. Many elderly patients cannot tolerate
aggressive chemotherapy. Our findings suggest that low-dose
chemotherapy might be useful for elderly osteosarcoma patients by
preventing new metastasis when used in combination with
radiation therapy or as maintenance therapy.
EGR1 has received much attention recently because of its wide
range of activities as a transcription factor. Remarkably, EGR1
can exert effects as either a growth promoter or a tumor
suppressor. EGR1 may induce or suppress cell proliferation or
induce apoptosis of cancer cells [10,16,24–27]. Our MTT assay
Figure 7. EGR1 prevents osteosarcoma cell migration into blood vessel in vivo. GFP expression virus-transfected 143B cells were
inoculated into the knee joint. To examine tumour cell invasion of blood vessels, we counted GFP- positive- 143B cells within 50 ml blood aspirates
from hearts at 5 weeks after inoculation (A). The number of GFP- positive cells in blood was decreased in EGR1 -expressing 143B- inoculated mice (B)
[error bars represent mean (SD)] (P,0.05). Metastatic nodules in lungs were evaluated under fluorescence microscopy. Six of 6 control cell-inoculated
mice exhibited lung metastases. Four of six (66.7%) EGR1-expressing cell-inoculated mice exhibited lung metastases. The percent of lung metastasis
area was calculated by Lumina Vision (C).
doi:10.1371/journal.pone.0016234.g007
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had no effect on osteosarcoma cell growth. Our findings suggest
that the expression of EGR does not have general effects on
growth and instead exerts regulatory effects that appear to be cell-
type-specific.
We showed up-regulation of EGR1 following cisplatin,
methotrexate, etoposide, or doxorubicin treatment, each of which
exerts cytotoxic effects by different pharmacological mechanisms.
EGR1 can be rapidly induced by many stimuli, including growth
factors, cytokines, ultraviolet light, anti-tumour agents, and various
stresses [8,10,24, Cao, 1992 #88,25,28–35]. The distinct types of
stress caused by anti-tumor drugs might promote up-regulation of
EGR1, although anti-tumor drugs exert different pathways.
Further, we examined which signaling pathway promotes EGR1
expression following anti-tumor agent treatment. We treated
osteosarcoma cell lines with anti-tumor agent and some specific
inhibitors including ERK inhibitor, HIF1-a inhibitor, JAK2
inhibitor, LY294002, and others but we were unable to inhibit
EGR1 expression effectively. Further examination for regulation
mechanisms of EGR1 expression is needed.
The principle mode of action of doxorubicin, an anthracycline
antibiotic, appears to be its ability to cross-link DNA and RNA,
thereby affecting DNA and RNA synthesis [36,37]. However,
recent studies have demonstrated that genotoxic (i.e.,D N A
damaging) agents, including many important cancer chemother-
apy drugs, can have significant and selective effects on the
expression of certain inducible genes [38]. It has also been
demonstrated that noncytotoxic doses of the DNA cross-linking
cancer chemotherapy drugs MMC, cisplatin, and carboplatin
were effective at significantly altering the expression of the
MDR1 gene coding for the multidrug resistance protein P-
glycoprotein [37]. We were therefore interested in whether
chemotherapy agents might similarly alter the expression of
inducible invasion-related genes, and thereby potentially alter
tumor invasiveness, and found that anti-tumour agents increased
the expression of EGR1, and EGR1 decreased that of uPA and
uPAR.
The uPA system is thought to play roles in several different
processes important to tumor progression including angiogenesis,
tumor growth, and metastasis [39]. Expression of uPA and uPAR
frequently indicates a poor prognosis, and is in some cases
predictive of invasion and metastasis. uPAR is also thought to play
roles in the growth and metastasis of human osteosarcoma
[40–44]. We showed that forced expression of EGR1 inhibited
expression of uPA and uPAR. In addition, EGR1 decreased the
activity of uPA. These findings suggest that up-regulation of EGR1
following chemotherapy inhibits osteosarcoma migration via uPA
system. Many signaling pathways activate transcription factors
that act on the uPAR promoter, driving uPAR expression in
cancer [45]. uPAR transcription is controlled by ERK through
activator protein 1 transcription factors [46]. Hypoxia-inducible
factor 1a drive uPAR expression through a hypoxia responsive
element in the uPAR promoter [47]. Nuclear factor-kB also
activates uPAR expression [48]. Thus, multiple signaling inputs
can up-regulate uPAR transcription in tumors. We could not
detect the pathways that promote down-regulation of uPA/uPAR.
Further examination for regulation mechanisms of uPA/uPAR
system is needed.
Recently, many molecular target drugs have been developed
[49–52]. In addition, several Notch signal inhibitors have been
tested as molecular target drugs [53–55]. We previously reported
that activation of Notch signaling promotes the progression of
human osteosarcoma [56]. We examined the EGR1 expression by
c-secretase inhibitor, a pharmacological agent known to effectively
block Notch activation. EGR1 was up-regulated by c-secretase
inhibitor in human osteosarcoma cell lines (data not shown). These
findings suggest that EGR1 expression will also be up-regulated by
molecular target drugs.
In summary, anti-tumor agents increased the expression of
EGR1, and EGR1 decreased osteosarcoma invasion. Our findings
suggest that even though chemotherapy could not prevent
osteosarcoma growth in chemotherapy poor responders, chemo-
therapy prevents osteosarcoma cell migration into blood vessel by
down-regulation of urokinase plasminogen activation via up-
regulation of EGR1 during chemotherapy periods.
Supporting Information
Figure S1 Anti-tumor agent treatment increased the
expression of EGR1. Following 48 h or 5 days drug treatments,
total RNA extracted from osteosarcoma cell lines were analyzed
by real-time PCR. Following 48 h treatment, cisplatin, metho-
trexate, etoposide or doxorubicin increased EGR1 expression in
143B cell and Saos-2 cells. Following 5 days treatment, cisplatin
increased EGR1 expression in 143B cell. Following 5 days
treatment, etoposide or doxorubicin increased EGR1 expression
in Saos-2 cells. The comparative Ct (DDCt) method was used to
determine fold change in expression using GAPDH or ACTB.
Experiments were performed in triplicate with similar results
[error bars represent mean (SD)].
(TIF)
Figure S2 Chemotherapy increased EGR1 expression.
Total RNA extracted from osteosarcoma patients’ biopsy
specimens and excised tumors following chemotherapy were used
for real-time PCR. Real-time PCR revealed that 3 of 3 excised
specimens of osteosarcoma increased EGR1 expression 7.87- to
1.73-fold (A). One day after 4 mg doxorubicin treatment, RNA
was extracted from tumor in nude mice xenograft models. Real-
time PCR revealed that low dose chemotherapy increased EGR1
expression in vivo (B) (P,0.05). The comparative Ct (DDCt)
method was used to determine fold change in expression. These
experiments were performed in triplicate with similar results [error
bars represent mean (SD)].
(TIF)
Figure S3 Forced expression of EGR1 does not affect
osteosarcoma cell growth in vitro. We transfected control
vector or EGR1 expression vector, and examined osteosarcoma
cell growth. MTT assay revealed that growth of viable 143B, Saos-
2, and HOS cells over 8 days was not affected by forced expression
of EGR1 (A). These experiments were performed in triplicate with
similar results [error bars represent mean (SD)]. Colony formation
assay revealed that forced expression of EGR1 did not affect the
number of colonies in soft agar (B). These experiments were
performed in triplicate with similar results [error bars represent
mean (SD)].
(TIF)
Figure S4 Forced expression of EGR1 decreased the
expression of uPA and uPAR. Cell lysate were prepared from
control vector or EGR1 expression vector stably transfected cells.
ELISA assay showed that forced expression of EGR1 decreased
the expression of uPA and uPAR proteins in 143B (P,0.05) (A).
The expression of uPA and uPAR decreased in Saos-2 and HOS
(P,0.05) (B, C). These experiments were in triplicate with similar
results [error bars represent mean (SD)].
(TIF)
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creased the expression of uPA and uPAR. Following 24 h
drug treatments, total RNA extracted from osteosarcoma cell lines
were analyzed by real-time PCR. Treatment with cisplatin,
methotrexate, etoposide or doxorubicin decreased uPA and uPAR
expression in 143B and Saos-2 cells (P,0.05). The comparative Ct
(DDCt) method was used to determine fold change in expression
using GAPDH or ACTB. Experiments were performed in triplicate
with similar results [error bars represent mean (SD)].
(TIF)
Figure S6 Chemotherapy prevents expression of uPA
and uPAR by down-regulation of EGR1. Twenty four hours
after 4 mg doxorubicin treatment, RNA was extracted from
tumour in nude mice xenograft model. Real-time PCR revealed
that chemotherapy decreased uPA and uPAR expression in vivo (A)
(P,0.05). To examined whether EGR1 affects the expression of
uPA and uPAR in vivo. RNA was prepared from tumor formed by
control vector or EGR1 expression vector transfected cells. Real-
time PCR revealed that forced expression of EGR1 decreased uPA
and uPAR expression in vivo (B) (P,0.05). The comparative Ct
(DDCt) method was used to determine fold change in expression
using GAPDH. These experiments were performed in triplicate
with similar results [error bars represent mean (SD)].
(TIF)
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